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Background/aim: Primary thyroid lymphoma (PTL) is a very rare thyroid malignancy. It should be diagnosed and treated
immediately and accurately. Our aim was to evaluate the diagnostic methods and treatment results for patients with PTL.
Materials and methods: We retrospectively evaluated the records of 11 patients with PTL from 2009 to 2015, diagnosed at our institute.
Age, sex, stage, histopathologic type, presence of Hashimoto’s thyroiditis, diagnostic methods, treatment types, and recurrence were
examined.
Results: Six patients were female, 5 were male, and the median age of the patients was 61 years (range: 15–76 years). All patients had
a large palpable mass in the neck. Fine needle aspirate (FNA) biopsy was performed in all patients; however, it was useful only in the
diagnosis of 7 patients. Excisional and surgical biopsy was performed in 4 patients. All patients had non-Hodgkin B-cell lymphoma,
including 9 cases of diffuse large B-cell lymphoma (DLBCL), and 2 patients had mucosa-associated lymphoid tissue (MALT) lymphoma.
Recurrence was observed in one patient. Median survival was 34 months.
Conclusions: The preferred option for the diagnosis of PTL should be FNA biopsy, and the treatment should be decided on according
to whether the disease is limited to the thyroid gland or not, its histological type, and its stage.
Key words: Lymphoma, primary thyroid lymphoma, diagnostic methods, treatment

1. Introduction
Primary thyroid lymphoma (PTL) is quite a rare malignancy,
constituting 1%–5% of all thyroid malignancies, and 2% of
all extranodal lymphomas (1). It is seen more frequently
in females with chronic Hashimoto’s thyroiditis, with 3–4fold higher incidence than in male patients. PTL incidence
peaks in the mid-sixties; hence, half of PTL patients are
between the age of 60 and 79 years (2,3).
The most frequent complaint is a large
palpable swelling in the neck that resembles anaplastic
thyroid cancers. Diagnosis must be performed rapidly due
to differences in treatment. A large neck mass triggered by
PTL also causes symptoms such as dysphagia, dyspnea, and
hoarseness due to mass effect, which is typically associated
with the disease. In addition to these symptoms, some
patients may show B symptoms such as fever, night sweats,
and weight loss of 10% and higher in the last 6 months.
Histopathologically, PTLs appear in the form of
B-cell and T-cell type non-Hodgkin’s lymphomas (4).
B-cell non-Hodgkin lymphoma, which is the most
* Correspondence: kursatdikmen@yahoo.com
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frequent type of PTL, is classified as mucosa-associated
lymphoid tissue (MALT) lymphoma, diffuse large B-cell
lymphoma (DLCBL), and mixed type (5). In addition,
it has histological subtypes that are less frequent such
as follicular lymphoma, small lymphocytic lymphoma,
Burkitt’s lymphoma of the thyroid, primary thyroid mantle
cell lymphoma, and primary thyroid T-cell lymphoma (6–
10).
Fine needle aspirate (FNA) biopsy is frequently used
to diagnose the disease, but is not always successful (11).
Therefore, core needle biopsy or surgical biopsy is used
in such cases (12,13). PTLs are typically sensitive to
chemotherapy and radiotherapy and, hence, the role of
surgery in treatment is restricted. The five-year survival
rate of a PTL patient that is accurately diagnosed and
treated is stated to be 90% (12). Therefore, accurate
diagnosis and rapid targeted treatment are vital in these
PTL cases. In this study, clinical and histopathological
features of 11 patients with PTL were evaluated in terms
of the means of preparative diagnosis and postoperative
follow-up data.
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2. Materials and methods
2.1. Inclusion criteria and collection of the demographic
data
Eleven patients with PTL were evaluated retrospectively
in our center between 2009 and 2015. During this time,
we performed 1824 various thyroidectomy operations.
Histopathological results of the 309 patients were
malignant thyroid diseases, and for 11 of these patients
the histopathological diagnosis was primary thyroid
lymphoma. We included these 11 patients in our study.
Age, sex, diagnostic modality, stage, histopathologic
type, Hashimoto’s thyroiditis existence, thyroid function
tests, sedimentation values, ultrasonographic features of
the mass, treatment protocols, recurrence, and overall
survival status were evaluated. Hashimoto’s thyroiditis
was diagnosed when there was lymphocytic infiltration
in the thyroid glands, according to the pathologic report,
or the presence of antithyroglobulin or antimicrosomal
antibody. FNA biopsy, core needle biopsy, and surgical
biopsy were used for diagnosis. Ultrasonography
(USG) findings were correlated with pathologic results.
Patients who had systemic disease were excluded from
the evaluation.
2.2. Histopathologic evaluation and staging of the
patients
The diagnostic criteria of thyroid lymphoma
and its subtypes are very well established, both
histopathologically and immunohistochemically (14).
B-cell type non-Hodgkin’s lymphoma was classified
into 3 subtypes, namely MALT lymphoma, DLBCL,
and mixed type. Staging of the patients was performed
according to the Ann Arbor staging system (15).
According to this system, Stage I is regarded as disease
localized to the thyroid, Stage II is characterized as
disease localized to the thyroid and regional lymph node
basins, Stage III is the disease involving both sides of the
diaphragm, and Stage IV is regarded as disseminated
disease.
2.3. Treatment
The treatment of thyroid lymphoma depended on
histology, patient comorbidities, and performance status.
Management included chemotherapy, radiotherapy,
and a combination treatment of chemotherapy and
radiotherapy. The most commonly used chemotherapy
regimens were cyclophosphamide, doxorubicin,
vincristine, and prednisolone (CHOP) and Rituximab
with CHOP (R-CHOP).
2.4. Statistical evaluation
The evaluated parameters were computerized and
evaluated with IBM SPSS 20.0 (IBM Co., Armonk, NY,
USA). Descriptive statistics are presented as median,
frequency, and percentage.

3. Results
3.1. Patient demographics
The median age of the 11 patients examined in this study
was 61 years (range: 15–76 years). Six were female (54.5%),
five were male (45.5%), and the female/male ratio was 1.2.
The median age of females was 60 years (range: 36–76
years), and the median age of males was 54 years (range:
15–65 years). In our institute, the prevalence of PTL is
about 3.5%. The mean follow-up period of the patients was
34 months (range: 19–70 months). Although all patients
had a large palpable swelling in the neck, only five patients
(45.5%) had symptoms of compression. One patient
(9.1%) had type B symptoms, including fever, night sweats,
and weight loss. Although FNA biopsy was performed in
all patients, only 7 (63.6%) could be diagnosed as having
PTL. Two patients (18.2%) were diagnosed by excisional
biopsy, and 2 (18.2%) were diagnosed by surgical excision
(Table 1). All patients were euthyroid.
3.2. Histopathologic evaluation and staging of the
patients
Histopathologic evaluation revealed DLBCL [n = 9
(81.8%)], and two other patients had MALT lymphoma
(18.2%). Five (45.5%) were at Stage IE, 4 (36.4%) were at
IIE, 1 (9.1%) was at IIIE, and 1 (9.1%) was at IVE (Table 1).
3.3. Evaluation of research parameters
Ultrasonographic examination of the masses revealed
that lesions were hypoechoic for 6 (54.5%) patients and
isoechoic for 5 (45.5%) (Table 1).
Seven (63.6%) patients received only chemotherapy.
On the other hand, four (36.4%) underwent both
chemotherapy and radiotherapy. Average length followup of the patients was 34 (19–70) months. Only one patient
(9.1%) with histologic subtype DLBCL had recurrence,
observed after a 20-month follow-up period (Table 1).
The clinical and radiologic features of the patients are
summarized in Table 2. Five (55.6%) of the nine patients
with DLBCL were female and four (44.4%) were male.
All patients had a large palpable swelling in the neck.
Furthermore, three patients (33.3%) had dyspnea, one
patient (11.1%) had dysphonia, and one patient (11.1%)
had both dyspnea and dysphonia as associated symptoms.
Three patients (33.3%) with DLBCL had a history of
Hashimoto’s thyroiditis.
Two patients (one female, 50%) with a histologic
subtype of MALT lymphoma presented with cervical mass
as the primary complaint. One female (50% of the patients)
had Hashimoto’s thyroiditis history. Biopsy was used for
definitive diagnosis in both, and the stages of the disease
in these patients were Stages IE and IIE, respectively.
MALT lymphoma lesions appeared to be hypoechoic on
the ultrasonographic examination. One patient (50%)
received chemotherapy as the primary therapy. On the
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Table 1. Summary of demographic, histopathologic, and
diagnostic parameters of the patients.
n (%)
Age (years)

54 (36–66)

Sex
Female

6 (54.5)

Male

5 (45.5)

Symptom
Sudden neck swelling

6 (54.5)

Dyspnea + sudden neck swelling

3 (27.3)

Dysphonia + sudden neck swelling

1 (9.1)

Dyspnea + dysphonia + neck swelling

1 (9.1)

Concomitant Hashimoto’s thyroiditis
No

7 (63.6)

Yes

4 (36.4)

Diagnostic method
Surgical excision

2 (18.2)

Excisional biopsy

2 (18.2)

FNA

7 (63.6)

Histologic type
DLCLL

9 (81.8)

MALT lymphoma

2 (18.2)

Stage
IE

5 (45.5)

IIE

4 (36.3)

IIIE

1 (9.1)

IVE
Low-grade malignancy
Intermediate-grade malignancy
High-grade malignancy

1 (9.1)
2 (18.2)
3 (27.3)
6 (54.5)

Ultrasonographic findings
Hypoechoic

6 (54.5)

Isoechoic

5 (45.5)

Treatment
Chemotherapy only

7 (63.6)

Chemotherapy + radiotherapy

4 (36.4)

Recurrence
No

10 (90.9)

Yes

1 (9.1)

Follow-up period (months)

34 (19–70)
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other hand, the other patient (50%) received a combination
of chemotherapy and radiotherapy. During the median
follow-up period, recurrence did not develop in these
patients.
4. Discussion
PTL is a rare disease entity that is frequently seen in females
with chronic Hashimoto’s thyroiditis (16). PTL is seen to
occur on average between the ages of 59 and 71 years (16).
Its female/male ratio is 3–4/1, and it has been reported to
appear 10 years earlier in men than in women (3,6,17).
Females constituted 54.5% of all patients in our study, and
female/male ratio was 6/5. This female dominance can
be due to autoimmune thyroid diseases occurring more
commonly in women. It is thought that there may be a link
between PTL and Hashimoto’s thyroiditis (lymphocytic
thyroiditis). The risk for PTL is increased by 67%–80% in
patients with Hashimoto’s thyroiditis (18,19). Our study
has indicated that Hashimoto’s thyroiditis is commonly
associated with PTL.
The most frequent symptoms are dyspnea and
hoarseness, related to the large palpable mass in the neck
leading to compression symptoms and/or infiltration of
the surrounding neck tissues (16,20). In 10% of patients,
type B symptoms can be seen such as fever, night sweat,
and weight loss (21). Symptoms of hypothyroidism can be
seen at a rate of 10%; however, most patients are reported
to be euthyroid (22). In our study, the clinical symptoms of
the patients were similar to those in the literature.
Ultrasonography is usually the first imaging modality
performed of a thyroid mass. PTL generally appears
as heterogeneous, intense hypoechoic areas, but these
findings are not specific (23), since they overlap with
anaplastic thyroid cancer. Furthermore, the diagnostic
accuracy of imaging methods, such as computerized
tomography, MR, and scintigraphy, is low. In this study,
the radiologic findings were similar to other study results
(24,25).
After imaging, the next diagnostic step accepted for
most thyroid masses is FNA biopsy. Although the sensitivity
of FNA biopsy for definitive diagnosis was low in previous
years due to certain limitations, the value of FNA biopsy
has increased in recent years, thanks to the advances in
immunohistochemical and flow cytometric methods.
However, an expert pathologist is needed for the diagnosis
of PTL with FNA biopsy, and it is absolutely necessary to
share with the pathologist that there may be a PTL, because
the ability of FNA biopsy in differentiating between
Hashimoto’s thyroiditis and PTL is unreliable (25,26).
Furthermore, differentiation between undifferentiated
thyroid carcinomas and PTL cannot always be made by
FNA biopsy, due to the existence of low-grade malignancy.
In the study by Matzuka et al. involving 119 patients, it
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Table 2. Clinical and radiologic characteristics of the patients according to the histologic subtype
of the primary thyroid lymphomas.
MALT lymphoma
(n = 2)

DLCLL
(n = 9)

n (%)

n (%)

Sex
Female

1 (50.0)

5 (55.6)

Male

1 (50.0)

4 (44.4)

2 (100)

4 (44.4)

Symptom
Sudden neck swelling
Dyspnea + sudden neck swelling

0

3 (33.3)

Dysphonia + sudden neck swelling

0

1 (11.1)

Dyspnea + dysphonia + neck swelling

0

1 (11.1)

Hashimoto’s thyroiditis
No

1 (50.0)

3 (33.3)

Yes

1 (50.0)

6 (66.7)

Diagnostic method
Surgical excision

0

2 (22.3)

Excisional biopsy

2 (100)

0

FNA

0

7 (77.7)

Stage
IE

1 (50.0)

4 (44.4)

IIE

1 (50.0)

3 (33.3)

IIIE

0

1 (11.1)

IVE

0

1 (11.1)

Hypoechoic

2 (100)

4 (44.4)

Isoechoic

0

5 (55.6)

Chemotherapy only

1 (50.0)

6 (66.7)

Chemotherapy + radiotherapy

1 (50.0)

3 (33.3)

Ultrasonographic findings

Treatment

Recurrence
No

2 (100)

8 (88.9)

Yes

0

1 (11.1)

was reported that the diagnoses of 78% of patients were
confirmed with FNA biopsy (27). The study by Matzuka
et al. reported intermediate and high-grade malignancy
in 77% of the patients. In our study, only 7 cases (63.6%)
were diagnosed by FNA biopsy alone. In the present study,
2 patients (18.2%) had low-grade malignancy, 3 patients
(27.2%) had intermediate malignancy, and 6 patients
(54.5%) had high-grade malignancy. Additionally, there
were 3 patients who were assessed as suspicious for thyroid
lymphoma with FNA biopsy. Large needle or excisional

biopsy are recommended as other methods for diagnosis
(22). The study by Sharma et al. suggested core needle
biopsy as the first diagnostic step when thyroid lymphoma
is suspected (23). However, we selected excisional biopsy,
because it provides clearer histopathological information
and shows the exact degree of malignancy. In addition,
this would likely decrease the repeat biopsy interventions.
In the last three decades, the role of surgery in thyroid
lymphomas has changed. While previously, surgery was
thought to be the primary treatment, today the primary
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treatments are chemotherapy and radiotherapy (28–30).
Despite this regression of surgical treatment, 61% of
patients with thyroid lymphoma are reported to have
undergone surgery for various reasons between 1997 and
2005, according to the SEER database analysis (6). Due
to providing quick decompression in MALT lymphoma,
in patients with thyroid-localized diseases or lifethreatening compression symptoms, surgical treatment is
still performed today (3,9,31–34). In fact, according to the
SEER database analysis, the long-term results of patients
treated only with surgery or with surgery and radiotherapy
are reported to be better than those treated only with
chemotherapy (6). In our study, a thyroidectomy was
performed in one patient, whose FNA biopsy diagnosis was
reported as suspicious for anaplastic carcinoma.
Histopathologic type and stage are the most important
factors that determine prognosis for PTL patients. DLBCL
is more aggressive than MALT lymphoma, and according
to other studies, the five-year disease survival rate is
approximately 75% (3,9,32). MALT lymphoma is frequently
restricted to the thyroid and is determined at an early stage
(5). Disease-specific survival rate is 96% (3,6). The mixed
type has a similar clinical course to DLBCL (12). Stage is
one of the factors that affects PTL prognosis. Generally, as
the stage progresses, the possibility of survival decreases.
According to a population-based study, five-year survival
rate is 86% at Stage IE, 81% at Stage IIE, and decreases to
64% at Stages IIIE and IVE (12). In this study, 9 patients
(81.8%) are at Stages IE and IIE. Recurrence occurred in
one patient (9.1%), who was at Stage IIIE.
Thyroid lymphomas are tumors that are responsive to
radiotherapy and chemotherapy; these should be given
prior consideration in primary treatment. If the tumor
is localized to the thyroid gland, external beam radiation
can be preferred for primary treatment. Response to
radiotherapy is dramatic and enables quick shrinkage of the

tumor. However, relapses have been reported in about 30%
of patients, even if the disease was at Stage IE or IIE (29).
For this reason, the dominant view is that even if it appears
to be a localized disease, there is a need for combination
chemotherapy regimens. Chemotherapy is used as a
primary treatment in advanced diseases or in combination
with radiotherapy in localized diseases. The combination
chemotherapy regimen usually consists of CHOP and
R-CHOP. Rituximab is a monoclonal antibody that
selectively binds to the CD20 antigen found on the surface
of pre-B and mature B lymphocytes (35). Meta-analysis of
published reports on primary nodal lymphoma patients
verifies the superiority of adding rituximab to combination
chemotherapy (36). Several other monoclonal antibody
drugs are entering clinical practice (e.g., obinutuzumab,
ofatumumab, and ibritumomab) (37). In our study, 5
patients with DLBCL received R-CHOP chemotherapy
regimen, and 1 received only CHOP regimen therapy.
One patient with MALT lymphoma received R-CHOP
chemotherapy regimen. Prospective randomized studies
are still needed to determine the best method of diagnosis
and treatment. However, the fact that it is a very rare disease
and that the number of patients is limited makes it almost
impossible for such studies to be conducted.
In conclusion, PTL is a disease with good prognosis after
treatment, performed according to whether it is limited
to the thyroid gland, low grade, Stage IE, or according
to its histological type. PTL is very similar to anaplastic
thyroid carcinomas in terms of symptoms. Therefore, rapid
accurate diagnosis and initiation of prompt therapy are
important. The FNA biopsy can be used initially; however,
if pathologic diagnosis is suspicious and PTL diagnosis is
supported by clinical features, other diagnostic tools can
be used. Creating a standardized diagnosis protocol and
effective treatment modality for PTL requires further
studies with a larger number of patients.
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